Moreover, previous studies have also shown that PI3K inhibition sensitizes CSCs to chemotherapy and molecular targeted therapy in several cancers including leukemia, hepatocellular carcinoma and breast cancer [51-53]. The gene discussed is PIK3CA; the disease is leukemia.